 By John Vandermosten, CFA NASDAQ:LPCN READ THE LATEST LPCN RESEARCH REPORT Lipocine NASDAQ:LPCN held its post action meeting with the FDAs Division of Bone, Reproductive and Urologic Products in mid-January and recently received the minutes of the meeting. On February 24th the company announced that, according to FDA feedback, it will be able to address the remaining outstanding deficiency 